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Accuracy of genotyping for HPV16 and 18 to triage women with low-
grade squamous intraepithelial lesions: a pooled analysis of VALGENT 
studies 
 
Background:  
Genotyping for the most carcinogenic HPV types (HPV16/HPV18) can identify high risk of 
underlying cervical precancer and guide further management.  
Research design and methods:  
A pooled analysis was performed of the clinical accuracy of high-risk HPV testing and 
HPV16/18 genotyping in triage of women with low grade squamous intraepithelial lesions 
(LSIL).  Data regarding 24 assays evaluated in four VALGENT validation panels were used.  
Results: 
In women with LSIL, hrHPV had a pooled sensitivity for CIN2+ of 95.5% (95% CI: 91.0-
97.8%) and a specificity of 25.3% (95% CI: 22.2-28.6%). HPV16/18 genotyping had a 
sensitivity and specificity for CIN2+ of 52.9% (95% CI: 48.4-57.4%) and 83.5% (95% CI: 
79.9-86.5%), respectively. The average risk of CIN2+ was 46.1% when HPV16/18-positive, 
15.5% in women who were HPV16/18-negative but positive for other hrHPV types and 4.3% 
for hrHPV-negative women.  
Conclusions: 
Triage of women with LSIL with HPV16/18 genotyping increases the positive predictive 
value compared to hrHPV testing but at the expense of lower sensitivity. Arguably, women 
testing positive for HPV16/18 need further clinical work-up. Whether colposcopy referral or 
further surveillance is recommended for women with other hrHPV types may depend on the 
post-test risk of precancer and the local risk-based decision thresholds.  
Keywords: Cervical cancer screening, human papillomavirus, HPV genotyping, triage, low-
grade squamous intraepithelial lesions, diagnostic test accuracy 
1. Introduction 
In women with minor cytological abnormalities, atypical squamous cells of undetermined 
significance (ASC-US), triage with high-risk human papillomavirus (hrHPV) testing is 
recommended in many cervical cancer screening protocols worldwide  [1,2]. For moderate 
cytological abnormalities, low-grade squamous intraepithelial lesions (LSIL),  triage with 
hrHPV testing is less informative due to the high prevalence of HPV  [2,3], and the 
management of LSIL positive women is divergent across settings [2,3]. To avoid immediate 
referral of all LSIL patients to colposcopy and the adverse effects of overtreatment, triage 
tools are needed to identify the minority of women with LSIL with underlying or incipient 
high-grade lesions. Partial genotyping for HPV16 and HPV18 has been proposed as a 
candidate triage marker. A previous systematic review and meta-analysis [4], published in 
2017, indicated that although genotyping for HPV16 and HPV18 has poor sensitivity, it may 
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be useful as an additional triage tool in LSIL hrHPV positive women in a two-step triage 
scenario. Here, a risk-based decision-making tool based on post-test risk is presented [4]. 
The number of commercially available HPV assays enabling HPV16 and HPV18 typing 
capabilities has increased substantially in the past five years as clinical focus is changing 
from simple detection of hrHPV towards extended or full genotyping [1,5-8]. Current 
evidence on the usefulness of HPV16 and HPV18 typing as a triage for the management of 
women with LSIL is here updated using new accuracy data obtained from the international 
VALidation of HPV GENotyping Tests (VALGENT) framework. VALGENT aims for the 
comparison and validation of HPV genotyping tests for clinically relevant outcomes using 
sample-populations relevant for primary cervical cancer screening [5]. An important 
objective of VALGENT is to document the accuracy of genotyping for the triage of women 
with minor cytological abnormalities and the contribution of more than twenty new accuracy 
datasets on the triage of women with LSIL will complete the current evidence base [4]. 
In the current pooled analysis of four individual VALGENT studies, we assess the accuracy 
of genotyping for HPV16/18 in triage of women with LSIL cytology to identify women with 
underlying cervical intraepithelial  neoplasia of grade 2 or worse (CIN2+). The pre-test and 
post-test risks of CIN2+ were computed to suggest management decisions based on agreed 
threshold levels [4]. 
2. Materials and Methods 
2.1 VALGENT framework and sample collection 
The VALGENT framework contains several iterative sample panels collated in different 
countries. Up to now, three VALGENT panels have been completed with a fourth ongoing. 
VALGENT-1 were provided by the AML laboratory using SurePath collected samples 
(Antwerp, Belgium) [9-13], VALGENT-2 by the Scottish HPV Reference Laboratory using 
ThinPrep collected samples (Edinburgh, Scotland) [14-16], VALGENT-3 were performed 
using ThinPrep collected samples from the Laboratory for Molecular Microbiology of 
University of Ljubljana (Ljubljana, Slovenia) [17-21], and VALGENT-4 using fresh 
SurePath collected samples by the Molecular Pathology Laboratory of Copenhagen 
University Hospital (Copenhagen, Denmark) [22]. In each VALGENT panel, the study 
population comprised a continuous series of 1,000 or 1,300 cervical specimen (archived or 
fresh) from women participating in the local cervical cancer screening programme 
supplemented with  300 abnormal pathological samples (100 ASC-US, 100 LSIL and 100 
high-grade squamous intraepithelial lesions [HSIL]) [5]. Detailed information about each 
panel collection, processing and manipulation can be found in previously published 
VALGENT reports [9-22]. 
2.2 Clinical outcomes and performance measurement 
According to the VALGENT protocol [5], we considered the presence of histologically 
confirmed CIN2+ as main disease outcome identified through follow-up and management 
according to national guidelines. Colposcopy was triggered by abnormal cytology in 
VALGENT-2 [14,15], and by abnormal cytology and/or positive hrHPV testing in 
VALGENT-1, -3 and -4 [5,22,23]. For the purpose of current pooled analysis of triage 
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accuracy, we use the number of women found with LSIL cytology and subsequently detected 
CIN2+ as the denominator for the computation of clinical sensitivity. Specificity was 
evaluated on women with LSIL index cytology and with normal colposcopy/histology 
findings and/or a negative cytology outcome through the follow-up period. 
2.3 Evaluated tests in VALGENT studies 
The full name, abbreviated name and the type specific remit of the evaluated assays, 
delivered in the VALGENT testing laboratories are summarised in Table 1. Throughout the 
rest of the paper, assays will be labelled by their shortened name. In total, twenty-four 
different HPV assays were evaluated in this pooled-analysis. Five assays have limited HPV 
genotyping capacity, which can identify HPV16 and HPV18 separately (Cobas, Abbott, 
HPVRisk, HybribioHR and Harmonia); two has extended genotyping capacity (Onclarity and 
Xpert) and seventeen were full genotyping assays identifying at least 14 hrHPV types 
(HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, 
HPV58,HPV59, HPV66 and HPV68) separately (Riatol qPCR, BSGP5 +/6+ MPG, GP5+/6+ 
LMNX, TS-E7-MPG, PapilloCheck, Linear Array, AnyplexHR, Anyplex HPV28, Innolipa, 
Euroarray, Papiloplex, Genoarray, LifeRiver Venus, CLART, Massarray, Modified GP5+/6+ 
and BGI).  
The evaluated index tests were HPV assays identifying HPV16 alone or HPV16 and HPV18 
jointly (HPV16/18). A positive HPV16/18 test was considered positive if HPV16 and/or 
HPV18 were present and negative when both types are absent. The comparator tests were 
hrHPV testing with GP5+/6+ PCR EIA (VALGENT-2 and VALGENT-4) and HC2 
(VALGENT-3).  These two tests are accepted as the standard comparator tests in the 
validation of new HPV assays with potential application for primary cervical cancer 
screening [24].  In VALGENT-1, the aggregate of 14 hrHPV types identified with the 
RIATOL qPCR was used as comparator test since no results generated by HC2 or GP5+/6+ 
PCR-EIA were available. For Euroarray, the optimised cut-off proposed in the previously 
published VALGENT report was used for current analysis [19]. The cut-off set by the 
individual assay manufacturer was used without modification for all the rest evaluated assays.  
To triage women with LSIL in order to detect CIN2+, the following questions on test 
accuracy of the different HPV genotyping assays were addressed: 1) what is the absolute 
clinical accuracy (sensitivity and specificity) of genotyping for HPV16 alone or for HPV16 
and HPV18 combined (HPV16/18);  2) what is the relative clinical accuracy of genotyping 
for HPV16/18 compared to general hrHPV testing; 3) what is the relative accuracy of 
combined HPV16/18 genotyping compared to HPV16 genotyping alone; and 4) what is the 
clinical accuracy of HPV16/18 genotyping when considered as a second triage step in the 
management of hrHPV-positive LSIL women. 
2.4 Statistical analysis 
A bivariate normal model for the logit transformations of sensitivity and specificity were 
used to compute the pooled absolute sensitivity and specificity [25,26]. The relative 
sensitivity and specificity of the evaluated index tests versus the comparator test were 
computed by including the test as a covariate in the bivariate normal model [27,28]. 
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Summary receiver-operating characteristics (sROC) plots were used to illustrate the joint 
overall and study-specific sensitivity and specificity of genotyping for HPV16 and HPV16/18 
and hrHPV testing for triage of women with LSIL. Statistical analyses were conducted with 
STATA 14 (Stata Corp., College Station, Tex) using metandi25 and a user-written procedure 
allowing multivariate diagnostic test accuracy meta-regression.  
3 Results 
3.1 Characteristics of study populations in different VALGENT panels 
In VALGENT-1, 122 women with LSIL at enrolment(mean age: 33, range: 15-65)  had 
follow-up outcomes with 15 CIN2+ cases identified. The total number of LSIL patients at 
enrolment with valid clinical outcomes in VALGENT-2 and -3 were 98 (mean age: 30.5, 
range: 19-62)  and 47 (mean age: 35.4, range: 20-65]), respectively.  According to the 
VALGENT protocol and the routinely indicated follow-up and management procedure in 
Scotland and Slovenia, in total, 20 and 22 confirmed CIN2+ cases were identified 
respectively. The VALGENT-4 study is on-going, with follow-up data until March 2018; 
from this 62 LSIL patients (mean age: 39.0, range: 30-57) and 14 CIN2+ were identified. 
3.2 Absolute accuracy of genotyping for HPV16 and HPV16/18 compared to hrHPV 
testing  
 HPV16/18 genotyping identified, on average, 52.9% (95% CI: 48.4-57.4%) of CIN2+ while 
the pooled specificity to exclude CIN2+ was 83.5% (95% CI: 79.9-86.5%) (Figure 1). The 
pooled absolute accuracy measures for the genotyping of HPV16 and HPV16/18 and the 
hrHPV testing in triage of women with LSIL to detect underlying CIN2+ with 95% 
confidence intervals (CIs) are reported in Table 2. The sROC plot displays the sensitivity and 
specificity of the hrHPV testing (red), of genotyping for HPV16 (blue) and of HPV16/18 
(green) in the triage of women with LSIL to detect CIN2+ (Figure 2).  
3.3 Relative accuracy of HPV16 and HPV16/18 compared to each other and compared 
to hrHPV testing  
Genotyping of HPV16 and HPV16/18 demonstrated substantially higher specificity for the 
detection of CIN2+, compared with testing for hrHPV types. The pooled specificity ratios 
were 3.40 (95% CI: 2.97-3.89; p<0.0001) and 3.20 (95% CI: 2.81-3.64; p<0.0001 ), 
respectively (Table 4). The sensitivity of the two partial genotyping methods was lower 
compared with the hrHPV testing for detecting CIN2+. The pooled ratios were 0.50 (95% CI: 
0.45-0.57; p<0.0001) for HPV16 genotyping and 0.57 (95% CI: 0.51-0.63; p<0.0001) for 
HPV16/18 genotyping.  HPV16/18 genotyping detected on average 13% more CIN2+ than 
HPV16 genotyping, although this was not statistically significant (p=0.06), whereas the 
specificity to exclude CIN2+ was on average 6% lower which reached significance (95% CI: 
3-9%; p<0.0001).  
3.4 Pre-test and post-test risk of cervical precancer 
In Table 4, the pre- and post-test probabilities of CIN2+ of two triage strategies are presented. 
The average risk of CIN2+ before triaging test (pre-test risk) was derived from a previously 
published meta-analysis [4].The post-test probabilities can be computed with the pre-test risk 
and the sensitivity and specificity derived from the current pooled analysis (Table 2). Women 
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with LSIL had on average a risk of CIN2+ of 21% before triaging test, triage with a hrHPV 
test stratifies this risk to25.4% if hrHPV-positive and 4.3% if hrHPV-negative. Triage testing 
with HPV16/18 positive increased the risk of CIN2+ to 46.1%. Women testing HPV16/18 
negative contain two subgroups: a) women who are hrHPV negative and b) those who are 
positive for other hrHPV types.  They have a risk of CIN2+ of 13.0%.  
A new pooled-analysis was performed to evaluate the accuracy of triage with HPV16/18 
genotyping for CIN2+ restricted to hrHPV positive women (Figure 3). The pooled sensitivity 
and specificity were 58.1% (95% CI: 53.1-62.5%) and 76.5% (95% CI: 72.5-80.0%), 
respectively. The post-test risk of CIN2+ is shown in the last row in Table 4; here the pre-test 
risk of CIN2+ corresponds with the post-test risk for triage with hrHPV testing (25.4%) with 
risks of 45.2% (if HPV16/18 positive) and 15.5% (if HPV16/18-negative, but other hrHPV-
positive).   
4 Discussion 
This pooled analysis demonstrates the utility and the limitations of genotyping for HPV16 
and HPV16/18 in triage of women with LSIL cytology. We found that HPV16 genotyping 
detects around half of women with LSIL cytology and underlying CIN2+. The addition of 
HPV18 to HPV16 only genotyping increased the sensitivity for CIN2+ with 13% but 
decreased the specificity with 6%. Due to the substantially larger number of <=CIN1 cases 
than CIN2+ cases, differences were significant for the specificity but not statistically 
significant for sensitivity. The pooled specificity of HPV16/18 genotyping to exclude CIN2+ 
is 84%, which was, as expected, substantially more specific but less sensitive than testing for 
all hrHPV types. 
The underlying risk of cervical precancer should determine management [29]. A good triage 
test to manage LSIL patients should have good discriminatory power to indicate colposcopy 
referral when the triage test is positive and a return to either routine screening or re-test at a 
defined interval when the triage test is negative. Based on results of test accuracy obtained 
from current pooled analysis and the knowledge of CIN2+ prevalence in women with LSIL 
from the previously published meta-analysis [4], the post-test probabilities of CIN2+ of 
different triage strategies could be computed and translated into patient management 
algorithms. 
A one-step HPV16/18 triage strategy clearly is not clinically acceptable since it does not 
allow to distinguish two groups (hrHPV negative and other than HPV16/18 positive) with 
clearly different risks.  When HPV16/18 genotyping is applied in a two-step triage scenario 
to hrHPV-positive, its sensitivity is slightly higher, and its specificity is slightly lower 
compared to HPV16/18 when applied as a single triage.  
The average risk of underlying CIN2+, pooled from the VALGENT studies, was 46% if 
HPV16/18-positive, 16% in women who were positive for other hrHPV types but negative 
for HPV16/18 and 4% for LSIL hrHPV-negative women. In European settings, a risk of 
CIN2+ (or positive predictive value) of >20% has been proposed as a threshold to indicate 
colposcopy [30-32]; an interval for surveillance testing 6-12 months later could be proposed 
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if the risk of CIN2+ is between 2-20%, and an interval for routine testing three years later is 
proposed if the risk for CIN2+ is <2%. In contrast, in the USA, if the risk of CIN2+ exceeds 
10.2%, colposcopy referral is proposed [33]. Summarizing, use of HPV16 and/or 18 positive 
outcomes in women with LSIL could be considered useful in a European setting, effectively 
selecting those women who would have a colposcopy referral versus those with other hrHPV 
types who can be referred for re-testing at a defined interval. 
With genotyping capability being an increasing feature of HPV testing platforms, our 
findings of the current study may help inform patient management pathways for women with 
LSIL through description of the underlying risks associated with HPV16/18 positivity.  
In total, we included 24 HPV tests, which performed overall similarly with respect to clinical 
sensitivity and specificity in the different triage scenarios. However, limitations should be 
noted. First, in VALGENT, cross-sectional and short-term longitudinal endpoints are defined 
in agreement with the local follow-up guidelines within a single screening round.  The 
follow-up periods for screen-positive women varied between 0 and 20 months. Short-term 
outcomes do not provide insights on the risk of developing high-grade disease over time. 
How the sensitivity and specificity of HPV16/18 genotyping change between cross-sectional 
or longitudinal endpoint has been assessed in a previously published meta-analysis  [4]. The 
absolute longitudinal sensitivity of genotyping for HPV16/18 (>=2 years after the index 
finding of LSIL) was 12-15 percent lower whereas the longitudinal specificity was 1-2 
percent higher than the respective cross-sectional accuracy measures. Another limitation was 
the small number of LSIL women who had a final diagnosis of CIN3+ in each of the 
VALGENT panels (always <10). Although it would be better to use histologically confirmed  
CIN3+ as main disease outcome, the low number of CIN3+ would make the sensitivity 
estimations unstable and imprecise. Therefore, we had to restrict our analysis to the endpoint 
of CIN2+. 
The pooled results are comparable with the evidence in the previously published meta-
analysis of genotyping with HPV16/18 in women with low grade cervical lesions [4]. It 
suggests that partial genotyping tests can be used to risk stratify precancer in hrHPV-positive 
women and to inform about need for immediate colposcopy or re-test within a defined 
interval. However, the clinical utility of HPV16/18 genotyping in LSIL patients is moderate, 
since negative triage results do not bring down the risk to a sufficiently low level allowing for 
a safe relieve to routine screening.  Therefore research for more performant triage markers 
should be continued. Since LSIL reflects a prevalent HPV infection, finding appropriate 
triage markers might be a relevant setting to discover triage tests that are also useful for the 
management of  hrHPV-positive women in a context of primary HPV-based screening.  
5 Conclusion 
In Conclusion, triage of women with LSIL with partial genotyping of HPV16/18 increases 
the positive predictive value compared to detection of all hrHPV types but at the expense of 
loss in sensitivity. Women testing positive for HPV16/18 need further diagnostic and/or 
therapeutic work-up. Women testing HPV16/18-negative but positive for other hrHPV types 
may also be referred to colposcopy or kept under further surveillance depending on local 
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decision thresholds. HrHPV-negative LSIL patients may be kept under surveillance or 
released to routine screening also depending on local decision thresholds. Further 
development and optimization of triage markers is needed to manage women with LSIL 
beyond limited genotyping. 
6 Five-year view 
Triage of minor cytology will stay important in several countries as long as cytology remains 
the primary cervical cancer screening test. Additional triage options beyond genotyping for 
HPV16 and 18 which allow better management are still needed.  However, it is expected that 
within 5 years, many countries will have switched to HPV-based cervical cancer screening. 
In the future, triage of HPV-positive women will become a major topic for new meta-
analytical work. However, defining evidence-based algorithms for management will continue 
to be driven by the assessment of risks of significant disease and how these risks change by 
screening and triage tests.  
 
Key issues 
• Triage of women with LSIL by HPV16/18 genotyping in a one-step triage strategy is 
poorly sensitive and not clinically acceptable.  
• Genotyping for HPV16/18 to triage women with LSIL may be useful as a second 
triage test for women testing hrHPV-positive. 
• Women with LSIL testing positive for HPV16/18 can be referred to colposcopy 
directly. 
• Women with LSIL testing positive for other hrHPV types may also be referred to 
colposcopy or maintained under surveillance depending on local decision thresholds. 
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Figure 1. Pooled analysis of the sensitivity (left) and specificity (right) of genotyping for HPV16/18 to detect CIN2+ in women with LSIL.  
CIN: cervical intra-epithelial neoplasia; HPV: human papillomavirus; LSIL: low-grade squamous intraepithelial lesion. 
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Figure 2. Summary receiver operation characteristic plot of the sensitivity as a function of the specificity of hrHPV and genotyping for 
HPV16/18 and HPV16 alone to detect CIN2+ in women with LSIL. 
CIN: cervical intra-epithelial neoplasia; HPV: human papillomavirus; hr: high-risk; LSIL: low-grade squamous intraepithelial lesion. 
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Figure 3. Pooled analysis of the sensitivity (left) and specificity (right) of genotyping for HPV16/18 to detect CIN2+ in women with LSIL who 
were hrHPV-positive. CIN: cervical intraepithelial lesion. HPV: human papillomavirus; hr: high-risk; LSIL: low-grade squamous intraepithelial 
lesion. 
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Table 1. Characteristics of the different HPV tests evaluated in VALGENT framework 
Assay (abbreviated name; 
manufacturer) 
Performed by Evaluated in 
Valgent No: 
Test genotyping capacity 
Standard comparator tests 
* Hybrid Capture 2 High-Risk 
HPV DNA Test (HC2; Qiagen, 
Gaithersburg, MD, USA)  
Laboratory for Molecular 
Microbiology, Faculty of Medicine, 
University of Ljubljana, Slovenia 
3 No separate genotyping. Detects  13 hrHPV types in aggregate: 
16,18,31,33,35,39,45,51,52,56,58,59 and 68.  
 
* GP5+/6+ PCR- EIA (GP5+/6+ 
EIA; Diassay B.V., Rijkswijk, 
the Netherlands) 
DDL Diagnostic Laboratory, 
Rijswijk, The Nederland 
1,2,4 No separate genotyping. Detections in bulk 14 hrHPV types in aggregate: 
same as HC2 plus 66. 
Evaluated tests 
1 Riatol qPCR assay (Riatol 
qPCR; lab in-house assay) 
AML laboratory, Antwerp, Belgium 1,2,3 Individual detection of: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68; 
Detects also phr type 53 and lr types 6 & 11. 
2 BSGP 5+/6+-PCR/MPG assay 
(BSGP5 +/6+ MPG; lab in-
house assay) 
Department of Genome 
Modifications and Carcinogenesis, 
DKFZ, Heidelberg, Germany 
1 Individual detection of: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 
68b;pHr types 26, 53, 67, 70, 73, 82, 6, 11, 30, 42, 43, 44, 7, 13, 32, 34, 40, 
54, 61, 62, 71, 72, 74, 81, 83, 84, 85, 86, 87, 89, 90, 91, 97, 102, 106, 55, 64 
and 68a.  
3 GP5+/6+ PCR Luminex 
genotyping kit (GP5+/6+ 
LMNX; Diassay B.V., 
Rijkswijk, the Netherlands) 
DDL Diagnostic Laboratory, 
Rijswijk, The Nederland 
1,2,4 Individual detection of 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68; 
Detects also phr types: 26,53,73,82. 
4 TS-E7-MPG assay (TS-E7-
MPG; in-house assay) 
IARC, Lyon, France 1 Individual detection of 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 
66, 68, 70, 73, and 82.  
5 BD Onclarity HPV assay 
(Onclarity; BD Diagnostics, 
Sparks, MD, USA) 
SHRL, Edinburg, Scotland 
& Hvidovre Hospital, Dept. 
Pathology, Hvidovre, Denmark 
2, 4 Individual detection of 16, 18, 31, 45, 51, 52, 33/58, 56/59/66 and 35/39/68. 
6 Xpert HPV (Xpert; Cepheid, 
Sunnyvale, CA, USA) 
SHRL, Edinburg, Scotland 2 16, 18/45 and 11 other hrHPV types (See GP5+/6+ PCR- EIA). 
7 PapilloCheck HPV-screening 
(PapilloCheck; Greiner Bio-
One, Frickenhausen, Germany) 
French HPV Reference Laboratory, 
Institut Pasteur, Paris, France. 
2 Individual detection of 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 
68, 70, 73, 82, 6, 11, 40, 42, 43, 44. 
8 Linear Array HPV genotyping 
(Linear Array; Roche 
Laboratory for Molecular 
Microbiology, Faculty of Medicine, 
University of Ljubljana, Slovenia 
3 Individual detection of 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 
82, 6, 11, 40, 42, 54, 61, 70, 72, 81, CP6108, 55, 62, 64, 67, 69, 71, 83, 84, 
and IS39. 
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Molecular Diagnostics, 
Branchburg, NJ, USA) 
9 Cobas 4800 HPV test (Cobas; 
Roche Molecular System, 
Pleasanton, CF, USA) 
Laboratory for Molecular 
Microbiology, Faculty of Medicine, 
University of Ljubljana, Slovenia 
3 16,18 and 12 other hr types (See GP5+/6+ PCR- EIA) 
10 Abbott RealTime High Risk 
HPV test (Abbott; Abbott, 
Wiesbaden, Germany) 
Laboratory for Molecular 
Microbiology, Faculty of Medicine, 
University of Ljubljana, Slovenia 
3 16,18 and 12 other hr types (See GP5+/6+ PCR- EIA) 
11 Anyplex II HPV HR assay 
(AnyplexHR; Seegene, Seoul, 
South Korea)   
Laboratory for Molecular 
Microbiology, Faculty of Medicine, 
University of Ljubljana, Slovenia 
3 
 
Individual detection of 14 hrHPV types: 16,18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 66, 68 
12 Anyplex HPV28 detection assay 
(Anyplex28; Seegene, Seoul, 
South Korea) 
Laboratory for Molecular 
Microbiology, Faculty of Medicine, 
University of Ljubljana, Slovenia 
3 Separate identification of 28 types: 14 hr types (16,18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 66, 68);  6 phr types (26, 53, 69, 70, 73, 82); 8 lr types (6, 
11, 40, 42, 43, 44, 54, 61). 
13 INNO-LiPA Extra II HPV 
Genotyping assay (Innolipa; 
Fujirebio Europe, Ghent, 
Belgium) 
Ghent University Hospital, Ghent, 
Belgium 
3,4 Separate identification of 28 different HPV types, 14 hr types (16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68); 5 phr types (26,53,73, 70,82); 6 lr 
types ( 6, 11, 40, 43, 44, 54); 3 types with undetermined risk (69, 71, 74). 
14 EUROArray HPV (Euroarray; 
EUROIMMUN; Lübeck, 
Germany) 
SHRL, Edinburg, Scotland 3 Separate identification of 30 types: 14 hr types (16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 66, 68); 4phr types (26, 53, 73, 82); 12 lr or ur types (6, 
11, 40, 42, 43, 44, 54, 61, 70, 72, 81, 89). 
15 HPV-risk array (HPVRisk; Self-
screen BV, Amsterdam, The 
Netherlands)  
Cancer Center Amsterdam, VU 
University Medical Center, 
Amsterdam, The Netherlands 
3,4 HPV16, 18 and 13 other hr types ((See GP5+/6+ PCR- EIA plus 67) 
16 Hybribio 21 HPV Genoarray 
diagnostic kit (Genoassay; 
Hybribio, HongKong, China) 
Laboratory for Molecular 
Microbiology, Faculty of Medicine, 
University of Ljubljana, Slovenia 
3 Separate identification of 21 types: 14 hr types (16,18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 66, 68);  1 phr types (53); 6 lr types (6, 11, 42, 43, 44, 81). 
17 Hybribio 14 High-risk HPV with 
16/18 Genotyping Real-time 
PCR kit (HybribioHR; ; 
Hybribio, HongKong, China) 
Laboratory for Molecular 
Microbiology, Faculty of Medicine, 
University of Ljubljana, Slovenia 
3 16,18 & 12 other hr types (See GP5+/6+ PCR- EIA) 
18 Papilloplex High Risk HPV 
(Papiloplex; GeneFirst, 
Oxfordshire, UK) 
SHRL, Edinburg, Scotland 4 Individual detection of 14 hr types (See GP5+/6+ PCR- EIA) 
19 Liferiver Harmonia HPV assay 
(Harmonia; Liferiver, Shanghai, 
China) 
SHRL, Edinburg, Scotland 4 16,18 & 12 other hr types (See GP5+/6+ PCR- EIA) 
14 
 
20 Liferiver Venus HPV assay 
(LiferiverVenus; Liferiver, 
Shanghai, China) 
SHRL, Edinburg, Scotland 4 Separate identification of 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 
68 & 82 
21 CLART HPV4 assay (CLART; 
Genomica, Madrid, Spain) 
Hvidovre Hospital, Dept. Pathology, 
Hvidovre, Denmark 
4 Individual detection of : 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 
66, 68 
22 Agena HPV MassArray assay 
(Massarray; Agena Bioscience, 
Hamburg, Germany) 
Hvidovre Hospital, Dept. Pathology, 
Hvidovre, Denmark 
4 Individual detection of: 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 
59, 66, 67, 68, 73 
23 Modified GP5+/6+ PCR 
(Modified GP5+/6+; Karolinska 
University Hospital, Stockholm, 
Sweden) 
International HPV Reference 
Center, Karolinska University 
Hospital, Stockholm, Sweden 
4 Individual detection of 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68; 
Detects also phr types: 26,53,73,82. 
24 BGI SENTIS HPV test (BGI; 
Shenzhen, China)   
BGI Institute, HongKong, China  4 Individual detection of 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68; 
Detects also lr types: 6 & 11. 
hrHPV: high-risk HPV types; phr types: probably/possibly carcinogenic HPV types; lr types: low-risk HPV types.  
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Table 2. Pooled absolute sensitivity and specificity of genotyping for HPV16 and HPV1618 
and hrHPV testing in triage of women with LSIL to detect underlying CIN2+ 
     Pooled value, in % 
Genotyping Outcome No of Sensitivity 
(95% CI) 
Specificity 
    studies/tests (95% CI) 
HPV16 CIN2+ 30 46.9 (41.6-52.3) 89.2 (86.0-91.8) 
HPV16/18 CIN2+ 29 52.9 (48.4-57.4) 83.5 (79.9-86.5) 
HrHPV CIN2+ 32 95.5 (91.0-97.8) 25.3 (22.2-28.6) 
 
Table 3. Pooled analysis of the relative sensitivity and relative specificity of A) genotyping 
for HPV16 compared to hrHPV testing; B) genotyping for HPV16/18 compared to hrHPV 
testing and C) genotyping for HPV16/18 versus genotyping for HPV16 only, in triage of 
women with LSIL to detect CIN2+. 
 Number of Relative  Relative  
Outcome comparisons sensitivity P specificity p 
A) Comparison HPV16 vs hrHPV    
CIN2+ 30 0.50 (0.45-0.57) <0.0001   3.40 (2.97-3.89) <0.0001  
B) Comparison HPV16/18 vs hrHPV    
CIN2+ 29 0.57( 0.51-0.63) <0.0001   3.20 (2.81 –3.64) <0.0001  
C) Comparison HPV16/18 vs HPV16    
CIN2+ 32 1.13 (0.99-1.28)  0.06  0.94 (0.91-0.97) <0.0001  
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Table 4. Pre-test and post-test probabilities of CIN2+ of triage with hrHPV testing or 
HPV16/18 genotyping among women with LSIL. Data for triage with HPV16/18 genotyping 
among women hrHPV+ LSIL is shown in the grey row (two-step triage).  
Triage 
Group 
  
Test 
Pre-test 
risk* 
Post-test risk 
if test+ if test- 
PPV cNPV 
LSIL hrHPV 21%* 25.4% 4.3% 
  HPV16/18 21% 46.1% 13.0% 
LSIL&hrHPV+ HPV16/18 25% 45.2% 15.5% 
 
*Pre-test risk based on pooled prevalence from previously published meta-analysis 
(AIM2016). For triage of hrHPV-positive LSIL patient, the pre-test risk corresponds with the 
post-test risk after hrHPV testing. 
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